Paris: Is your blood group A, B or AB? Then we might have some bad news for you.
According to a recent study, having a non-O blood group can be associated with higher risks of heart attack.
The study’s lead author Tessa Kole, a Master’s degree student at the University Medical Centre Groningen, the Netherlands, said that it has been observed that people with non-O blood groups (A, B, AB) are at higher risk for heart attacks and overall cardiovascular mortality, but these findings only come from case-control studies that have a low level of confidence. If this was confirmed it could have important implications for personalised medicine.
The recent study was a meta-analysis of prospective studies reporting on O and non-O blood groups, and incident cardiovascular events including myocardial infarction (heart attack), coronary artery disease, ischaemic heart disease, heart failure, cardiovascular events and cardiovascular mortality.
The research included 1,362,569 subjects from eleven prospective cohorts, described in nine articles. There were a total of 23,154 cardiovascular events.
The scientists analysed the connection between blood group and all the coronary events, combined cardiovascular events, and fatal coronary events.
The study found that the analysis of all coronary events included 771,113 people with a non-O blood group and 519,743 people with an O blood group, of whom 11,437(1.5%) and 7220 (1.4%) suffered a coronary event.
The analysis of combined cardiovascular events included 708,276 people with a non-O blood group and 476,868 people with an O blood group, of whom 17 449 (2.5%) and 10,916 (2.3%) had an event, respectively. The OR for combined cardiovascular events was significantly higher in non-O blood group carriers, at 1.09 (95% CI 1.06-1.11).
The analysis of fatal coronary events did not show a significant difference between people with O and non-O blood groups.
“We demonstrate that having a non-O blood group is associated with a 9% increased risk of coronary events and a 9% increased risk of cardiovascular events, especially myocardial infarction,” said Ms Kole.
The mechanisms that might explain this risk are under study. The higher risk for cardiovascular events in non-O blood group carriers may be due to having greater concentrations of von Willebrand factor, a blood clotting protein which has been associated with thrombotic events.
Further, non-O blood group carriers, specifically those with an A blood group, are known to have higher cholesterol. And galectin-3, which is linked to inflammation and worse outcomes in heart failure patients, is also higher in those with a non-O blood group.
Ms Kole noted, “More research is needed to identify the cause of the apparent increased cardiovascular risk in people with a non-O blood group. Obtaining more information about risk in each non-O blood group (A, B, and AB) might provide further explanations of the causes.”
She concluded by saying, “In future, blood group should be considered in risk assessment for cardiovascular prevention, together with cholesterol, age, sex and systolic blood pressure.
It could be that people with an A blood group should have a lower treatment threshold for dyslipidaemia or hypertension, for example. We need further studies to validate if the excess cardiovascular risk in non-O blood group carriers may be amenable to treatment.”